Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

SABCS 2024

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC...

Dr Nan Chen - The University of Chicago, Chicago, USA

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Olaparib after chemotherapy continues to meaningfully improveme efficacy in...

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

Olaparib after chemotherapy continues to meaningfully improveme efficacy in gBRCApv and high-risk, HER2-negative primary BC ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

Immediate breast surgery versus deferral of surgery in women aged 70+ years...

Prof Robert Hills - University of Oxford, Oxford, United Kingdom

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer ( Prof Robert Hills - University of Oxford, Oxford, United Kingdom )

More from ecancer